KCNE4 (MiRP3) Antibody
Affinity purified polyclonal antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application ![]()
| WB |
---|---|
Primary Accession | Q9WTW3 |
Reactivity | Human, Mouse, Rat |
Host | Rabbit |
Clonality | Polyclonal |
Calculated MW | 18639 Da |
Homology | Rat, human-identical. |
Gene ID | 57814 |
---|---|
Other Names | Potassium voltage-gated channel subfamily E member 4, MinK-related peptide 3, Minimum potassium ion channel-related peptide 3, Potassium channel subunit beta MiRP3, Kcne4 |
Related products for control experiments | Control peptide antigen (supplied with the antibody free of charge). |
Target/Specificity | Peptide (C)GYMKSKRREKKSS, corresponding to amino acid residues 56- 68 of mouse KCNE4 (Accession Q9WTW3). Intracellular, C-terminus. |
Dilution | WB~~1:200-1:2000 |
Peptide Confirmation | Confirmed by mass-spectrography and amino acid analysis. |
Format | Affinity purified antibody, lyophilized powder |
Reconstitution | 25 µl, 50 µl or 0.2 ml deionized water, depending on the sample size. |
Antibody Concentration After Reconstitution | 0.8 mg/ml. |
Storage Before Reconstitution | Lyophilized powder can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C. |
Storage After Reconstitution | The reconstituted solution can be stored at 4ºC for up to 2 weeks. For longer periods, small aliquots should be stored at -20ºC or below. Avoid multiple freezing and thawing. The further dilutions should be made using a carrier protein such as BSA (1%). Centrifuge all antibody preparations before use (10000 × g 5 min). |
Control Antigen Storage Before Reconstitution | Lyophilized powder can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C. |
Control Antigen Reconstitution | 100 µl DDW. |
Control Antigen Storage After Reconstitution | -20ºC. |
Preadsorption Control | 2 µg peptide per 1 µg antibody. |
Formulation | Lyophilized powder. Reconstituted antibody contains phosphate buffered saline (PBS), pH 7.4, 1% BSA, 0.05% NaN3. |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abgent.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The K+ voltage-gated channel subfamily E member (KCNE) family is a group of small, non-conducting, single transmembrane domain proteins that associate with pore-forming potassium channel subunits to form mixed complexes with unique characteristics1. Five different KCNE proteins have been described (KCNE1-5)2. The KCNE regulatory subunits are small proteins (14-20 kD) with a type-1 integral membrane topology. It is believed that both the cytoplasmic C-terminus tail and the transmembrane domain are necessary for the interaction with the α subunits1. MinK-related peptides (MiRPs) MiRP3, protein encoded by KCNE43. The importance of these proteins to normal physiology of the heart and nervous system is exposed by their association with clinical disorders such as congenital long QT syndrome, drug-induced cardiac arrhythmias, sensorineural deafness, and periodic paralysis4. In addition, MiRPs influence the normal physiology of endocrine and exocrine glands, intestinal secretion, and renal excretion. MiRP3 is found to co-localize with KV4.2 subunits that contribute to cardiac transient outward K+ currents5. Levels of the KCNE4 transcript in human cardiac ventricle are robust and increase in patients with congestive failure suggesting a regulatory function for MiRP3 in the heart6. In addition to regulating KV4.2, MiRP3 also regulates KCNQ1 and BK channels2,5.
References
References 1. Abbott, G.W. et al. (1999) Cell 97, 175. 2. Grunnet, M. et al. (2002) J. Physiol. 542,119. 3. McCrossan, Z.A. and Abbott, G.W. (2004) Neuropharmacology 47, 787. 4. Levy, D.I. et al. (2008) Am. J. Physiol. 295, F380. 5. Levy, D.I. et al. (2010) J Physiol. 588, 2657. 6. Bendahhou, S. et al. (2005) Cardiovasc. Res. 67, 529.

If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.